PTK2 and non-small cell lung carcinoma: One of the major causes of this is the upregulation of αvβ3 integrin by osteopontin, which contributes to acquired gefitinib resistance in NSCLC cell lines PC9 through the activation of the FAK/AKT and ERK pathways [40].